Publication:
Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

dc.contributor.authorSalman, Andaç
dc.contributor.authorAlper, Sibel
dc.contributor.authorAtakan, Nilgün
dc.contributor.authorBorlu, Murat
dc.contributor.authorCanpolat, Filiz
dc.contributor.authorErdem, Teoman
dc.contributor.authorErdem, Yasemin
dc.contributor.authorGül, Ülker
dc.contributor.authorKartal, Selda Pelin
dc.contributor.authorKoca, Rafet
dc.contributor.authorKüçük, Özlem Su
dc.contributor.buuauthorBaşkan, Emel Bülbül
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDermatoloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-0144-3263
dc.contributor.researcheridAAH-1388-2021
dc.contributor.scopusid6602518817
dc.date.accessioned2023-11-02T10:42:30Z
dc.date.available2023-11-02T10:42:30Z
dc.date.issued2020-12
dc.identifier.citationSalman, A. vd. (2020). "Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology". Turkderm Turkish Archives of Dermatology and Venereology, 54(2), 71-75.
dc.identifier.endpage75
dc.identifier.issn2717-6398
dc.identifier.issn2651-5164
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85089913448
dc.identifier.startpage71
dc.identifier.urihttps://doi.org/10.4274/turkderm.galenos.2020.80000
dc.identifier.urihttps://jag.journalagent.com/turkderm/pdfs/TURKDERM_54_2_71_75.pdf
dc.identifier.urihttp://hdl.handle.net/11452/34757
dc.identifier.volume54
dc.identifier.wos000544409600008
dc.indexed.scopusScopus
dc.indexed.trdizinTrDizin
dc.indexed.wosESCI
dc.language.isoen
dc.publisherGalenos Yayıncılık
dc.relation.collaborationYurt içi
dc.relation.collaborationSanayi
dc.relation.journalTurkderm Turkish Archives of Dermatology and Venereology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDermatology
dc.subjectAtopic dermatitis
dc.subjectCovid-19
dc.subjectTreatment
dc.subjectUrticaria
dc.subjectOmalizumab
dc.subjectMetaanalysis
dc.subjectAtopik dermatit
dc.subjectCOVID-19
dc.subjectDupilumab
dc.subjectTedavi
dc.subjectÜrtiker
dc.subject.emtreeAzathioprine
dc.subject.emtreeCyclosporine
dc.subject.emtreeDupilumab
dc.subject.emtreeInterleukin 1beta
dc.subject.emtreeInterleukin 6
dc.subject.emtreeMethotrexate
dc.subject.emtreeMycophenolate mofetil
dc.subject.emtreeOmalizumab
dc.subject.emtreePrednisolone
dc.subject.emtreeAtopic dermatitis
dc.subject.emtreeCoronavirus disease 2019
dc.subject.emtreeCytokine storm
dc.subject.emtreeHuman
dc.subject.emtreeHypertension
dc.subject.emtreeImmunosuppressive treatment
dc.subject.emtreeImmunotherapy
dc.subject.emtreeInflammation
dc.subject.emtreeLetter
dc.subject.emtreeObesity
dc.subject.emtreePandemic
dc.subject.emtreeRandomized controlled trial (topic)
dc.subject.emtreeRisk factor
dc.subject.emtreeSevere acute respiratory syndrome coronavirus 2
dc.subject.emtreeShared decision making
dc.subject.emtreeSystemic therapy
dc.subject.emtreeUrticaria
dc.subject.scopusSkin; Allergic contact dermatitis; COVID-19
dc.subject.wosDermatology
dc.titleRecommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology
dc.title.alternativeCOVID-19 pandemisi süresince ürtiker ve atopik dermatitte sistemik tedavilerin kullanımına ilişkin öneriler: Türk Dermatoloji Derneği dermatoallerji çalışma grubu bildirisi
dc.typeLetter
dc.wos.quartileQ4
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dermatoloji Ana Bilim Dalı
local.indexed.atTrDizin
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Başkan_vd_2020.pdf
Size:
151.57 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: